A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
Trial details
- Registry ID
- NCT06162286
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABPNCT06162286 | Zai Lab (Hong Kong), Ltd. | Phase 3 | Unknown | 2025-01-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |